Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Ms. Deborah M. AutorIndependent Director | -34,82k | 450,56k | Verkauf | 12,94 | 93,66k | -27,10% |
| 2026-05-07 | Mr. J. Kevin BuchiIndependent Director | 34,82k | 0,00 | Derivative Exercise and Retained Stock | - | 337,15k | 11,52% |
| 2026-05-07 | Ms. Deborah M. AutorIndependent Director | 34,82k | 0,00 | Derivative Exercise and Retained Stock | - | 128,48k | 37,18% |
| 2026-05-07 | Mr. Jeffrey P. GeorgeIndependent Director | 34,82k | 0,00 | Derivative Exercise and Retained Stock | - | 344,61k | 11,24% |
| 2026-05-07 | Mr. Gautam PatelDirector | 34,82k | 0,00 | Derivative Exercise and Retained Stock | - | 1,64M | 2,16% |
| 2026-05-07 | Mr. John J. KielyIndependent Director | 34,82k | 0,00 | Derivative Exercise and Retained Stock | - | 260,25k | 15,45% |
| 2026-05-07 | Mr. Ted C. NarkIndependent Director | 34,82k | 0,00 | Derivative Exercise and Retained Stock | - | 325,85k | 11,96% |
| 2026-05-07 | Mr. Paul M. MeisterIndependent Chairman of the Board | 48,75k | 0,00 | Derivative Exercise and Retained Stock | - | 832,80k | 6,22% |
| 2026-05-07 | Mr. Shlomo YanaiIndependent Director | 34,82k | 0,00 | Derivative Exercise and Retained Stock | - | 320,80k | 12,18% |
| 2024-11-14 | Dipan PatelInsider | -6,92M | 86,01M | Verkauf | 7,74 - 12,42 | 16,90M | -29,06% |
| 2026-03-03 | Mr. Chirag K. PatelCo-Founder, Co-CEO, President & Director | 535,49k | 0,00 | Derivative Exercise and Retained Stock | - | 22,66M | 2,42% |
| 2026-03-03 | Mr. Chirag K. PatelCo-Founder, Co-CEO, President & Director | -350,98k | 4,67M | Derivative Exercise and Sale | 13,30 - 13,31 | 22,66M | - |
| 2026-03-03 | Mr. Chintu PatelCo-Founder, Co-CEO & Director | 524,49k | 0,00 | Derivative Exercise and Retained Stock | - | - | - |
| 2026-03-03 | Mr. Chintu PatelCo-Founder, Co-CEO & Director | -361,98k | 4,82M | Derivative Exercise and Sale | 13,30 - 13,31 | - | - |
| 2026-03-03 | Mr. Jason B. DalyExec. VP, Chief Legal Officer & Corporate Secretary | 241,18k | 0,00 | Derivative Exercise and Retained Stock | - | 251,78k | 2.273,98% |
| 2026-03-03 | Mr. Jason B. DalyExec. VP, Chief Legal Officer & Corporate Secretary | -185,64k | 2,47M | Derivative Exercise and Sale | 13,30 - 13,31 | 251,78k | - |
| 2026-03-03 | Mr. Anastasios G. KonidarisExec. VP & CFO | 327,28k | 0,00 | Derivative Exercise and Retained Stock | - | 449,43k | 267,93% |
| 2026-03-03 | Mr. Anastasios G. KonidarisExec. VP & CFO | -306,58k | 4,08M | Derivative Exercise and Sale | 13,30 - 13,31 | 449,43k | - |
| 2026-03-03 | Ms. Nikita ShahExec. VP & Chief HR Officer | 253,39k | 0,00 | Derivative Exercise and Retained Stock | - | 399,79k | 173,08% |
| 2026-03-03 | Ms. Nikita ShahExec. VP & Chief HR Officer | -255,11k | 3,40M | Derivative Exercise and Sale | 13,30 - 13,31 | 399,79k | - |
| 2026-03-03 | Mr. Andrew S. BoyerExec. VP and Chief Commercial Officer of Generics & Biosciences | 273,65k | 0,00 | Derivative Exercise and Retained Stock | - | 426,07k | 179,53% |
| 2026-03-03 | Mr. Andrew S. BoyerExec. VP and Chief Commercial Officer of Generics & Biosciences | -275,31k | 3,66M | Derivative Exercise and Sale | 13,30 - 13,31 | 426,07k | - |
| 2025-11-17 | Mr. Ted C. NarkIndependent Director | -50,00k | 586,00k | Verkauf | 11,72 | 291,03k | -14,66% |
| 2025-11-12 | Ms. Nikita ShahExec. VP & Chief HR Officer | -131,86k | 1,21M | Derivative Exercise and Sale | 2,75 - 11,92 | 146,40k | - |
| 2025-10-03 | Mr. Chintu PatelCo-Founder, Co-CEO & Director | 13,26M | 0,00 | Kauf | - | 25,62M | 107,26% |
| 2025-10-03 | Mr. Chintu PatelCo-Founder, Co-CEO & Director | -13,26M | 0,00 | Verkauf | - | 25,62M | -34,10% |
| 2025-08-27 | Mr. John J. KielyIndependent Director | -32,00k | 295,36k | Verkauf | 9,23 | 225,43k | -12,43% |
| 2025-08-22 | Ms. Nikita ShahExec. VP & Chief HR Officer | -120,83k | 1,17M | Verkauf | 9,50 - 9,66 | 146,40k | -45,22% |
| 2025-08-20 | Mr. Andrew S. BoyerExec. VP and Chief Commercial Officer of Generics & Biosciences | -175,00k | 1,16M | Derivative Exercise and Sale | 2,75 - 9,38 | 152,43k | - |
| 2025-08-20 | Mr. Andrew S. BoyerExec. VP and Chief Commercial Officer of Generics & Biosciences | -104,24k | 977,81k | Verkauf | 9,38 | 152,43k | -40,61% |
| 2025-08-14 | Ms. Nikita ShahExec. VP & Chief HR Officer | -71,69k | 666,04k | Verkauf | 9,29 | 267,24k | -21,15% |
| 2025-08-13 | Mr. Anastasios G. KonidarisExec. VP & CFO | -499,73k | 4,66M | Verkauf | 9,22 - 9,43 | 122,15k | -80,36% |
| 2025-08-12 | Ms. Nikita ShahExec. VP & Chief HR Officer | -50,00k | 452,00k | Verkauf | 9,04 | 338,93k | -12,86% |
| 2025-08-12 | Mr. Jason B. DalyExec. VP, Chief Legal Officer & Corporate Secretary | -22,00k | 199,10k | Verkauf | 9,05 | 10,61k | -67,47% |
| 2025-08-12 | Mr. Andrew S. BoyerExec. VP and Chief Commercial Officer of Generics & Biosciences | -33,44k | 302,60k | Verkauf | 9,05 | 256,67k | -11,53% |
| 2025-06-16 | Mr. Gautam PatelDirector | -94,91k | 761,15k | Automatic Disposition | 8,02 | 1,61M | -5,57% |
| 2025-06-10 | Mr. Gautam PatelDirector | -56,43k | 452,54k | Verkauf | 8,02 | 1,70M | -3,21% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
